Hologic study shows benefits of foetal fibronectin testing

Scientific Company News

Hologic has announced the findings of a study that demonstrates the health benefits that foetal fibronectin (fFN) testing can offer for new mothers.

Published this week in the journal ClinicoEconomics and Outcomes Research, the study found that women with symptoms of preterm labour who were discharged from the hospital without an fFN test were more likely to deliver their baby prematurely within three days.

“Hologic has reported new clinical data showing how foetal fibronectin testing in pregnant women could help guide better patient care.“

Moreover, it was shown that only 12 percent of pregnant women with symptoms of preterm labour received fFN screening, suggesting that the potential benefits of this testing approach are being missed in many cases.

The fFN test is a noninvasive assay that detects the presence of foetal fibronectin in vaginal secretions, offering a clinically proven predictive value for whether a woman is at risk of premature birth.

Dr Edward Evantash, medical director and vice-president of medical affairs for Hologic, said: "All mothers deserve the best possible perinatal care, and the fFN test is a useful tool that should be used for those who are experiencing symptoms of preterm labour."

Hologic has received European CE Mark approval for a quantitative fFN test, and is still trying to secure approval from US regulators.

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Science
Return to news